Some studies reveal that serotonin 2A receptor activation may not be necessary for the potential therapeutic effects of psychedelics.
The path toward therapeutic psychedelic-based drugs is becoming clearer as scientists understand more about how they are processed in the body.
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
A recent study indicates that the empathogenic effects of LSD may be independent of serotonin 2A receptor activation.
Is DMT produced in the brain? The answer remains unclear, but this 2019 study provides striking evidence supporting the neural-DMT synthesis hypothesis.
Changes in structural neuroplasticity start within 24 hours, are enduring, and may not be solely dependent on 5-HT2A.
Despite its euphoric effects, nitrous oxide is not considered psychedelic.